Hyperpigmentation during interferon-alpha therapy for chronic hepatitis C virus infection

被引:38
|
作者
Willems, M
Munte, K
Vrolijk, JM
Den Hollander, JC
Böhm, M
Kemmeren, MH
De Man, RA
Brouwer, JT
机构
[1] Erasmus Univ Hosp Rotterdam, Dept Hepatogastroenterol, NL-3000 CA Rotterdam, Netherlands
[2] Erasmus Univ Hosp Rotterdam, Dept Pathol, NL-3000 CA Rotterdam, Netherlands
[3] Univ Munster, Dept Dermatol, D-4400 Munster, Germany
[4] Univ Munster, Ludwig Boltzmann Inst Cell Biol & Immunobiol Skin, D-4400 Munster, Germany
关键词
chronic hepatitis C; combination therapy; hyperpigmentation; interferon-alpha; skin;
D O I
10.1046/j.1365-2133.2003.05422.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Many types of skin disorders concomitantly occur with hepatitis C virus infection. These skin lesions may be induced or worsened during antiviral therapy with interferon-alpha (IFN). To our knowledge, hyperpigmentation of the skin-and especially of the tongue-has not been reported so far. We describe two dark-skinned patients who developed hyperpigmented skin and tongue lesions during combination therapy with IFN and ribavirin. Immunohistochemical analysis of tongue biopsies confirmed the suspicion of melanin deposits in these areas of hyperpigmentation. We hypothesize that during interferon therapy, melanocytes may produce more melanin pigment in the presence of alpha-melanocyte stimulating hormone and sufficient amounts of tyrosine, leading to melanin deposits and clinical hyperpigmentation.
引用
收藏
页码:390 / 394
页数:5
相关论文
共 50 条
  • [21] Impact of occult hepatitis B virus infection on efficacy and prognosis of interferon-alpha therapy for patients with chronic hepatitis C.
    Hasegawa, I
    Orito, E
    Tanaka, Y
    Hirashima, N
    Sakakibara, K
    Ohno, T
    Sugauchi, F
    Suzuki, S
    Sakurai, M
    Fujiwara, K
    Ozasa, T
    Ueda, R
    Mizokami, M
    HEPATOLOGY, 2002, 36 (04) : 369A - 369A
  • [22] CHRONIC HEPATITIS-B VIRUS-INFECTION AND INTERFERON-ALPHA
    GOESER, T
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 1995, 10 (10) : 1793 - 1794
  • [23] HEPATITIS-C VIRUS-RNA RESPONSE TO INTERFERON-ALPHA THERAPY OF CHRONIC HEPATITIS-C
    ZAFAR, M
    ELLIS, M
    SIECK, JO
    ALFURAYH, O
    ALI, A
    AYUB, A
    ALFADDA, M
    GASTROENTEROLOGY, 1993, 104 (04) : A1023 - A1023
  • [24] LOSS OF HBSAG WITH INTERFERON-ALPHA THERAPY IN CHRONIC HEPATITIS-D VIRUS-INFECTION
    LAU, JYN
    KING, R
    TIBBS, CJ
    CATTERALL, AP
    SMITH, HM
    PORTMANN, BC
    ALEXANDER, GJM
    WILLIAMS, R
    JOURNAL OF MEDICAL VIROLOGY, 1993, 39 (04) : 292 - 296
  • [25] BIOPSYCHOSOCIAL CONSEQUENCES OF INTERFERON-ALPHA (IFN-ALPHA) THERAPY IN PATIENTS WITH CHRONIC HEPATITIS C INFECTION
    Baranyi, A.
    Meinitzer, A.
    Stepan, A.
    Matejka, J.
    Stauber, R.
    Rothenhaeusler, H. -B.
    EUROPEAN PSYCHIATRY, 2011, 26
  • [26] Intravenous interferon-alpha treatment of mixed cryoglobulinemia associated with chronic hepatitis C virus infection
    Zeller, V
    Cohen, P
    Nguyen, QT
    Lebon, P
    Dziri, S
    Ferrière, F
    Dény, P
    Guillevin, L
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2002, 20 (04) : 573 - 574
  • [27] Acute autoimmune hemolytic anemia during interferon-alpha therapy for chronic hepatitis C
    Landau, A
    Castera, L
    Buffet, C
    Tertian, G
    Tchernia, G
    DIGESTIVE DISEASES AND SCIENCES, 1999, 44 (07) : 1366 - 1367
  • [28] Ischemic colitis during pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C
    Leung, Yvette
    Urbanski, Stefan J.
    Schindel, Lynn
    Myers, Robert P.
    CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 20 (10) : 661 - 663
  • [29] Abrupt onset of diabetes during interferon-alpha therapy in patients with chronic hepatitis C
    Recasens, M
    Aguilera, E
    Ampurdanés, S
    Tapias, JMS
    Simó, O
    Casamitjana, R
    Conget, I
    DIABETIC MEDICINE, 2001, 18 (09) : 764 - 767
  • [30] Pharmacokinetics of ribavirin in combined interferon-alpha 2b and ribavirin therapy for chronic hepatitis C virus infection
    Tsubota, A
    Hirose, Y
    Izumi, N
    Kumada, H
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 55 (04) : 360 - 367